DE19956568A1
(en)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Method and medicament for inhibiting the expression of a given gene
|
US7601494B2
(en)
|
1999-03-17 |
2009-10-13 |
The University Of North Carolina At Chapel Hill |
Method of screening candidate compounds for susceptibility to biliary excretion
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
DE10100586C1
(en)
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Inhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal bases
|
WO2003070918A2
(en)
|
2002-02-20 |
2003-08-28 |
Ribozyme Pharmaceuticals, Incorporated |
Rna interference by modified short interfering nucleic acid
|
US8202979B2
(en)
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
DK2796553T3
(en)
|
2000-03-30 |
2019-09-30 |
Whitehead Inst Biomedical Res |
RNA Sequence-Specific Mediators of RNA Interference
|
ES2728168T3
(en)
|
2000-12-01 |
2019-10-22 |
Max Planck Gesellschaft |
Small RNA molecules that mediate RNA interference
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
EP1438405A1
(en)
*
|
2001-01-09 |
2004-07-21 |
Ribopharma AG |
Use of a double-stranded ribonucleic acid for specifically inhibiting the expression of a given target gene
|
WO2003035869A1
(en)
*
|
2001-10-26 |
2003-05-01 |
Ribopharma Ag |
Use of a double-stranded ribonucleic acid for specifically inhibiting the expression of a given target gene
|
US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
US20050148530A1
(en)
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
IL159756A0
(en)
|
2001-07-12 |
2004-06-20 |
Univ Massachusetts |
IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING
|
US10590418B2
(en)
|
2001-07-23 |
2020-03-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for RNAi mediated inhibition of gene expression in mammals
|
ES2386775T3
(en)
|
2001-07-23 |
2012-08-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for RNAi-mediated inhibition of mammalian gene expression
|
DE10163098B4
(en)
|
2001-10-12 |
2005-06-02 |
Alnylam Europe Ag |
Method for inhibiting the replication of viruses
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
EP1438409A1
(en)
*
|
2001-10-26 |
2004-07-21 |
Ribopharma AG |
Use of a double strand ribonucleic acid for treating an infection with a positive-strand rna-virus
|
DE10202419A1
(en)
|
2002-01-22 |
2003-08-07 |
Ribopharma Ag |
Method of inhibiting expression of a target gene resulting from chromosome aberration
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
AU2003207708A1
(en)
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase genes
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US7399586B2
(en)
|
2002-05-23 |
2008-07-15 |
Ceptyr, Inc. |
Modulation of biological signal transduction by RNA interference
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
US20040241854A1
(en)
|
2002-08-05 |
2004-12-02 |
Davidson Beverly L. |
siRNA-mediated gene silencing
|
EP1389637B1
(en)
*
|
2002-08-05 |
2012-05-30 |
Silence Therapeutics Aktiengesellschaft |
Blunt-ended interfering RNA molecules
|
BRPI0313202A8
(en)
|
2002-08-05 |
2016-08-16 |
Atugen Ag |
ADDITIONAL WAYS TO INTERFERE WITH RNA MOLECULES
|
US20050042646A1
(en)
|
2002-08-05 |
2005-02-24 |
Davidson Beverly L. |
RNA interference suppresion of neurodegenerative diseases and methods of use thereof
|
ES2627779T5
(en)
*
|
2002-08-05 |
2021-05-04 |
Silence Therapeutics Gmbh |
Additional new forms of interfering RNA molecules
|
US20080274989A1
(en)
|
2002-08-05 |
2008-11-06 |
University Of Iowa Research Foundation |
Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
|
JP4339852B2
(en)
|
2002-08-12 |
2009-10-07 |
ニュー・イングランド・バイオラブズ・インコーポレイティッド |
Methods and compositions for gene silencing
|
US7892793B2
(en)
|
2002-11-04 |
2011-02-22 |
University Of Massachusetts |
Allele-specific RNA interference
|
US9771586B2
(en)
|
2002-11-14 |
2017-09-26 |
Thermo Fisher Scientific Inc. |
RNAi targeting ZNF205
|
US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
WO2006006948A2
(en)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
US9839649B2
(en)
|
2002-11-14 |
2017-12-12 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
US9719094B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting SEC61G
|
US9719092B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting CNTD2
|
US10011836B2
(en)
|
2002-11-14 |
2018-07-03 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
DE10254214A1
(en)
*
|
2002-11-20 |
2004-06-09 |
Beiersdorf Ag |
Oligoribonucleotides for the treatment of degenerative skin symptoms by RNA interference
|
JP4526228B2
(en)
*
|
2002-11-22 |
2010-08-18 |
隆 森田 |
Novel therapeutic methods and therapeutic agents using RNAi
|
DE10302421A1
(en)
*
|
2003-01-21 |
2004-07-29 |
Ribopharma Ag |
New double-stranded interfering RNA, useful for inhibiting hepatitis C virus, has one strand linked to a lipophilic group to improve activity and eliminate the need for transfection auxiliaries
|
CA2527109A1
(en)
|
2003-05-30 |
2004-12-09 |
Nippon Shinyaku Co., Ltd. |
Oligo double-stranded rna inhibiting the expression of bcl-2 and medicinal composition containing the same
|
US20060178327A1
(en)
*
|
2003-05-30 |
2006-08-10 |
Yeung Wah Hin A |
Inhibition of gene expression by delivery of specially selected double stranded or other forms of small interfering RNA precursors enabling the formation and function of small interfering RNA in vivo and in vitro
|
EP1633767B1
(en)
|
2003-06-02 |
2018-11-21 |
University of Massachusetts |
Methods and compositions for controlling efficacy of rna silencing
|
US8309704B2
(en)
|
2003-06-02 |
2012-11-13 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNAi
|
US7750144B2
(en)
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
EP3604537B1
(en)
*
|
2003-06-13 |
2021-12-08 |
Alnylam Europe AG |
Double-stranded ribonucleic acid with increased effectiveness in an organism
|
EP1486564A1
(en)
*
|
2003-06-13 |
2004-12-15 |
Ribopharma AG |
SiRNA with increased stability in serum
|
CA2536333C
(en)
|
2003-08-28 |
2013-01-08 |
Jan Weiler |
Interfering rna duplex having blunt-ends and 3'-modifications
|
US8680063B2
(en)
|
2003-09-12 |
2014-03-25 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
US7947658B2
(en)
|
2003-09-12 |
2011-05-24 |
University Of Massachusetts |
RNA interference for the treatment of gain-of-function disorders
|
US20060134787A1
(en)
|
2004-12-22 |
2006-06-22 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
|
JP2007523649A
(en)
|
2004-02-10 |
2007-08-23 |
サーナ・セラピューティクス・インコーポレイテッド |
Inhibition of gene expression via RNA interference using multifunctional short interfering nucleic acids (multifunctional siNA)
|
US20060019914A1
(en)
|
2004-02-11 |
2006-01-26 |
University Of Tennessee Research Foundation |
Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
|
US20050277610A1
(en)
|
2004-03-15 |
2005-12-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
US20070265220A1
(en)
|
2004-03-15 |
2007-11-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
EP1747022A4
(en)
|
2004-04-23 |
2010-03-31 |
Univ Columbia |
INHIBITION OF HAIRLESS PROTEIN mRNA
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
EP2471923B1
(en)
|
2004-05-28 |
2014-08-20 |
Asuragen, Inc. |
Methods and compositions involving microRNA
|
EP1782321A4
(en)
|
2004-07-23 |
2009-11-04 |
Univ North Carolina |
Methods and materials for determining pain sensitivity and predicting and treating related disorders
|
WO2006022689A1
(en)
*
|
2004-08-06 |
2006-03-02 |
Applera Corporation |
Method and compositions for treating diseases targeting cd51
|
MX2007002043A
(en)
|
2004-08-16 |
2007-10-11 |
Quark Biotech Inc |
Therapeutic uses of inhibitors of rtp801.
|
JP5087924B2
(en)
|
2004-08-26 |
2012-12-05 |
日本新薬株式会社 |
Galactose derivatives, drug carriers and pharmaceutical compositions
|
JPWO2006025154A1
(en)
*
|
2004-08-30 |
2008-05-08 |
国立大学法人岐阜大学 |
Modified oligonucleotide
|
JP4991547B2
(en)
|
2004-09-28 |
2012-08-01 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
Oligoribonucleotides and methods of use thereof for the treatment of alopecia, acute renal failure and other diseases
|
EP2302051B1
(en)
|
2004-11-12 |
2015-01-07 |
Asuragen, Inc. |
Methods and compositions involving miRNA and miRNA inhibitor molecules
|
US8703769B2
(en)
|
2005-07-15 |
2014-04-22 |
The University Of North Carolina At Chapel Hill |
Use of EGFR inhibitors to prevent or treat obesity
|
US20070161591A1
(en)
|
2005-08-18 |
2007-07-12 |
University Of Massachusetts |
Methods and compositions for treating neurological disease
|
EP1764091B1
(en)
|
2005-09-15 |
2017-08-30 |
Marina Biotech, Inc. |
Improvements in or relating to amphoteric liposomes
|
WO2007039454A1
(en)
|
2005-09-20 |
2007-04-12 |
Basf Plant Science Gmbh |
Methods for controlling gene expression using ta-siran
|
US8093369B2
(en)
|
2005-10-11 |
2012-01-10 |
Ben Gurion University Of The Negev Research And Development Authority Ltd. |
Compositions for silencing the expression of VDAC1 and uses thereof
|
US7825099B2
(en)
|
2006-01-20 |
2010-11-02 |
Quark Pharmaceuticals, Inc. |
Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
|
DOP2007000015A
(en)
|
2006-01-20 |
2007-08-31 |
Quark Biotech Inc |
THERAPEUTIC USES OF RTP801 INHIBITORS
|
DE602007004463D1
(en)
|
2006-03-01 |
2010-03-11 |
Nippon Shinyaku Co Ltd |
GALACTOSEDERIVATE, MEDICAMENT AND MEDICAL COMPOSITION
|
US7910566B2
(en)
|
2006-03-09 |
2011-03-22 |
Quark Pharmaceuticals Inc. |
Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
|
FR2898908A1
(en)
|
2006-03-24 |
2007-09-28 |
Agronomique Inst Nat Rech |
Process, useful to prepare differentiated avian cells from avian stem cells grown in culture medium, comprises induction of stem cells differentiation by inhibiting expression/activity of gene expressed in the stem cells e.g. Nanog gene
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
EP2026843A4
(en)
|
2006-06-09 |
2011-06-22 |
Quark Pharmaceuticals Inc |
Therapeutic uses of inhibitors of rtp801l
|
AU2007306556B2
(en)
|
2006-10-13 |
2014-04-10 |
Marina Biotech, Inc. |
Improvements in or relating to amphoteric liposomes
|
JP2010507387A
(en)
|
2006-10-25 |
2010-03-11 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
Novel siRNA and method of using the same
|
CN101641010A
(en)
|
2007-01-26 |
2010-02-03 |
路易斯维尔大学研究基金会公司 |
Be used as the modification of the allochthon component of vaccine
|
US7872119B2
(en)
|
2007-02-26 |
2011-01-18 |
Quark Pharmaceuticals, Inc. |
Inhibitors of RTP801 and their use in disease treatment
|
WO2008109546A2
(en)
*
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting tgfbr gene expression and uses thereof
|
PL2129680T3
(en)
|
2007-03-21 |
2015-10-30 |
Brookhaven Science Ass Llc |
Combined hairpin-antisense compositions and methods for modulating expression
|
US7812002B2
(en)
|
2007-03-21 |
2010-10-12 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
|
DE102007029471A1
(en)
|
2007-06-20 |
2008-12-24 |
Novosom Ag |
New optional cationic sterols
|
DK2170403T3
(en)
|
2007-06-27 |
2014-06-16 |
Quark Pharmaceuticals Inc |
Compositions and Methods for Inhibiting the Expression of Proapoptotic Genes
|
EP2198050A1
(en)
|
2007-09-14 |
2010-06-23 |
Asuragen, INC. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
WO2009044392A2
(en)
|
2007-10-03 |
2009-04-09 |
Quark Pharmaceuticals, Inc. |
Novel sirna structures
|
US8071562B2
(en)
|
2007-12-01 |
2011-12-06 |
Mirna Therapeutics, Inc. |
MiR-124 regulated genes and pathways as targets for therapeutic intervention
|
US8614311B2
(en)
|
2007-12-12 |
2013-12-24 |
Quark Pharmaceuticals, Inc. |
RTP801L siRNA compounds and methods of use thereof
|
KR100949791B1
(en)
*
|
2007-12-18 |
2010-03-30 |
이동기 |
Novel siRNA Structure for Minimizing Off-target Effects and Relaxing Saturation of RNAi Machinery and the Use Thereof
|
EP3643782A1
(en)
|
2008-02-11 |
2020-04-29 |
Phio Pharmaceuticals Corp. |
Modified rnai polynucleotides and uses thereof
|
US8258111B2
(en)
|
2008-05-08 |
2012-09-04 |
The Johns Hopkins University |
Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
|
WO2009147684A2
(en)
|
2008-06-06 |
2009-12-10 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treatment of ear disorders
|
TWI455944B
(en)
|
2008-07-01 |
2014-10-11 |
Daiichi Sankyo Co Ltd |
Double-stranded polynucleotides
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
WO2010021718A1
(en)
|
2008-08-19 |
2010-02-25 |
Nektar Therapeutics |
Complexes of small-interfering nucleic acids
|
WO2010033246A1
(en)
|
2008-09-22 |
2010-03-25 |
Rxi Pharmaceuticals Corporation |
Rna interference in skin indications
|
WO2010059226A2
(en)
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition of map4k4 through rnai
|
EP2361306A1
(en)
|
2008-12-04 |
2011-08-31 |
OPKO Ophthalmics, LLC |
Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
EP2823810B9
(en)
|
2009-07-09 |
2019-10-30 |
Novosom Verwaltungs GmbH |
Amphoteric liposomes comprising imino lipids
|
WO2011035065A1
(en)
|
2009-09-17 |
2011-03-24 |
Nektar Therapeutics |
Monoconjugated chitosans as delivery agents for small interfering nucleic acids
|
ES2759003T3
(en)
|
2009-11-26 |
2020-05-07 |
Quark Pharmaceuticals Inc |
SiRNA compounds comprising terminal substitutions
|
CN102686729B
(en)
|
2009-12-18 |
2015-09-23 |
箭头研究公司 |
Be used for the treatment of the organic composite of HSF1 relative disease
|
WO2011083147A1
(en)
|
2010-01-08 |
2011-07-14 |
Cemm-Forschungsinstitut Für Molekulare Medizin Gmbh |
Wave1 inhibition in the medical intervention of inflammatory diseases and/or infections caused by a pathogen
|
CA2789125A1
(en)
|
2010-02-10 |
2011-08-18 |
Novartis Ag |
Methods and compounds for muscle growth
|
IL265674B2
(en)
|
2010-03-24 |
2024-05-01 |
Phio Pharm Corp |
Rna interference in dermal and fibrotic indications
|
WO2011119852A1
(en)
|
2010-03-24 |
2011-09-29 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering rnai compounds
|
EP2550001B1
(en)
|
2010-03-24 |
2019-05-22 |
Phio Pharmaceuticals Corp. |
Rna interference in ocular indications
|
US20130116304A1
(en)
|
2010-04-19 |
2013-05-09 |
Ernst R. Werner |
Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
|
EP2609198B8
(en)
|
2010-08-24 |
2018-03-28 |
Sirna Therapeutics, Inc. |
SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
|
US20130224192A1
(en)
|
2010-09-02 |
2013-08-29 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Method for the prognosis of the progression of cancer
|
EP2433644A1
(en)
|
2010-09-22 |
2012-03-28 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Breast cancer therapeutics
|
KR101328568B1
(en)
|
2010-10-22 |
2013-11-13 |
성균관대학교산학협력단 |
Nucleic Acid Molecule Inducing RNA interference and the Use Thereof
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
CA2836364C
(en)
|
2011-05-25 |
2021-01-26 |
Universite Paris Descartes |
Erk inhibitors for use in treating spinal muscular atrophy
|
MY163674A
(en)
|
2011-07-01 |
2017-10-13 |
Ngm Biopharmaceuticals Inc |
Compositions, uses and method for treatment of metabolic disorders and diseases
|
WO2013040251A2
(en)
|
2011-09-13 |
2013-03-21 |
Asurgen, Inc. |
Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
|
EP2766733A2
(en)
|
2011-10-14 |
2014-08-20 |
Inserm |
Biomarkers of renal disorders
|
CA2860676A1
(en)
|
2012-01-09 |
2013-07-18 |
Novartis Ag |
Organic compositions to treat beta-catenin-related diseases
|
WO2013104798A1
(en)
|
2012-01-12 |
2013-07-18 |
Cemm - Center For Molecular Medicine Of The Austrian Academy Of Sciences |
Modulators of immune responses
|
EP2853597B1
(en)
|
2012-05-22 |
2018-12-26 |
Olix Pharmaceuticals, Inc. |
Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
|
EP2700949A1
(en)
|
2012-08-24 |
2014-02-26 |
IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. |
Use of biliverdin reductase proteins as cancer marker
|
EP2914260A1
(en)
|
2012-10-31 |
2015-09-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preventing antiphospholipid syndrome (aps)
|
US9290557B2
(en)
|
2012-11-28 |
2016-03-22 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides
|
EP3798228A1
(en)
|
2012-11-28 |
2021-03-31 |
NGM Biopharmaceuticals, Inc. |
Compositions and methods for treatment of metabolic disorders and diseases
|
US9273107B2
(en)
|
2012-12-27 |
2016-03-01 |
Ngm Biopharmaceuticals, Inc. |
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
NZ630469A
(en)
|
2012-12-27 |
2017-02-24 |
Ngm Biopharmaceuticals Inc |
Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
US10369199B2
(en)
|
2013-10-28 |
2019-08-06 |
Ngm Biopharmaceuticals, Inc. |
Methods of using variants of FGF19 polypeptides for the treatment of cancer
|
JP6772062B2
(en)
|
2013-12-02 |
2020-10-21 |
フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. |
Cancer immunotherapy
|
PT3097122T
(en)
|
2014-01-24 |
2020-07-21 |
Ngm Biopharmaceuticals Inc |
Binding proteins and methods of use thereof
|
JP6681837B2
(en)
|
2014-03-11 |
2020-04-15 |
セレクティスCellectis |
Method for making T cells compatible with allogeneic transplantation
|
EP3137119B1
(en)
|
2014-04-28 |
2020-07-01 |
Phio Pharmaceuticals Corp. |
Methods for treating cancer using a nucleic acid targeting mdm2
|
WO2015183890A2
(en)
|
2014-05-28 |
2015-12-03 |
Ngm Biopharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders and diseases
|
AU2015277438B2
(en)
|
2014-06-16 |
2020-02-27 |
Ngm Biopharmaceuticals, Inc. |
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
KR102506169B1
(en)
|
2014-09-05 |
2023-03-08 |
피오 파마슈티칼스 코프. |
Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
|
RU2729161C2
(en)
|
2014-10-23 |
2020-08-04 |
ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. |
Pharmaceutical compositions containing peptide versions, and methods of using them
|
US10434144B2
(en)
|
2014-11-07 |
2019-10-08 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
|
WO2016140922A1
(en)
|
2015-03-02 |
2016-09-09 |
180 Therapeutics Lp |
Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
|
WO2017007825A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
WO2017007813A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
|
US10800843B2
(en)
|
2015-07-29 |
2020-10-13 |
Ngm Biopharmaceuticals, Inc. |
Beta klotho-binding proteins
|
WO2017029391A1
(en)
|
2015-08-20 |
2017-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating cancer
|
WO2017070151A1
(en)
|
2015-10-19 |
2017-04-27 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
|
AU2016353988B2
(en)
|
2015-11-09 |
2019-09-26 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders
|
CA3005411C
(en)
|
2015-11-16 |
2024-01-09 |
Olix Pharmaceuticals, Inc. |
Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3
|
CA3022874A1
(en)
|
2016-02-02 |
2017-08-10 |
Olix Pharmaceuticals, Inc. |
Treatment of atopic dermatitis and asthma using rna complexes that target il4ra, trpa1, or f2rl1
|
WO2017134526A1
(en)
|
2016-02-02 |
2017-08-10 |
Olix Pharmaceuticals, Inc. |
Treatment of angiogenesis-associated diseases using rna complexes that target angpt2 and pdgfb
|
US11072777B2
(en)
|
2016-03-04 |
2021-07-27 |
University Of Louisville Research Foundation, Inc. |
Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (VSELs)
|
JP6959654B2
(en)
|
2016-03-31 |
2021-11-02 |
エスリス ゲーエムベーハーethris GmbH |
New minimum UTR sequence
|
MA45328A
(en)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
|
MA45469A
(en)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
BETA-CATENIN NUCLEIC ACIDS AND THEIR USES
|
MA45349A
(en)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
EGFR NUCLEIC ACIDS AND THEIR USES
|
MA45470A
(en)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
KRAS NUCLEIC ACIDS AND THEIR USES
|
CN109072238B
(en)
|
2016-04-11 |
2022-05-24 |
奥利克斯医药有限公司 |
Treatment of idiopathic pulmonary fibrosis using RNA complexes targeting connective tissue growth factor
|
KR101916652B1
(en)
|
2016-06-29 |
2018-11-08 |
올릭스 주식회사 |
Compounds improving RNA interference of small interfering RNA and use thereof
|
EP3519582A1
(en)
|
2016-07-29 |
2019-08-07 |
Danmarks Tekniske Universitet |
Methods for decoupling cell growth from production of biochemicals and recombinant polypeptides
|
US11370841B2
(en)
|
2016-08-26 |
2022-06-28 |
Ngm Biopharmaceuticals, Inc. |
Methods of treating fibroblast growth factor 19-mediated cancers and tumors
|
US11591600B2
(en)
|
2017-02-10 |
2023-02-28 |
OliX Pharmaceuticals. Inc. |
Long double-stranded RNA for RNA interference
|
KR102656200B1
(en)
|
2017-06-16 |
2024-04-12 |
아이엠비에이 - 인스티튜트 퓌어 몰레쿨라레 바이오테크놀로지 게엠베하 |
Vascular organoids, methods of making and using said organoids
|
KR102623786B1
(en)
|
2017-12-06 |
2024-01-11 |
어비디티 바이오사이언시스 인크. |
Compositions and methods of treating muscle atrophy and myotonic dystrophy
|
CN108535480B
(en)
*
|
2018-03-05 |
2020-03-06 |
南通大学附属医院 |
Application of EphA8 gene in preparation of anti-breast cancer drug and diagnostic kit thereof
|
CN108490180B
(en)
*
|
2018-03-12 |
2020-03-10 |
南通大学附属医院 |
Application of EphA8 gene in preparation of gastric cancer drugs and diagnostic kit thereof
|
IL310900A
(en)
|
2020-03-19 |
2024-04-01 |
Avidity Biosciences Inc |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
BR112023016903A2
(en)
|
2021-02-26 |
2023-10-10 |
Ethris Gmbh |
AQUEOUS SUSPENSION FORMULATION FOR AEROSOL, NEBULIZER, AND AEROSOL FORMATION
|
EP4327829A1
(en)
|
2022-08-26 |
2024-02-28 |
Ethris GmbH |
Stabilization of lipid or lipidoid nanoparticle suspensions
|
WO2024042236A1
(en)
|
2022-08-26 |
2024-02-29 |
Ethris Gmbh |
Stable lipid or lipidoid nanoparticle suspensions
|